Global HIV Vaccine Market Research Report 2026

HIV Vaccine Market

The global HIV Vaccine market was valued at US$ million in 2025 and is anticipated to reach US$ million by 2032, at a CAGR of %from 2026 to 2032.

The 2025 U.S. tariff policies introduce profound uncertainty into the global economic landscape. This report critically examines the implications of recent tariff adjustments and international strategic countermeasures on HIV Vaccine competitive dynamics, regional economic interdependencies, and supply chain reconfigurations.

AIDS, or Acquired Immunodeficiency Syndrome (AIDS), is caused by the human immunodeficiency virus (HIV), also known as the AIDS virus. HIV can specifically attack and destroy human immune cells, causing damage to the human immune system, gradual loss of related immune functions, and gradually becoming the target of many diseases, leading to various serious opportunistic infections, tumors, etc. At present, AIDS has become an important public health issue that seriously threatens the health of people around the world. In 1981, doctors discovered the first known case of HIV in the United States, and since then, more than 40 million people have died from the virus. According to data from the United Nations AIDS Program, men who have sex with men, female sex workers and their clients, transgender people, and people who inject drugs are at high risk. The virus is transmitted through the exchange of body fluids of infected people, such as blood, semen, and vaginal excrement. The most common is during unprotected sex, pregnancy and childbirth, transfusion of contaminated blood, or sharing of hypodermic needles. The human body cannot completely eliminate HIV. Therefore, once infected with the virus, an individual will remain HIV positive for life. However, through antiretroviral therapy (ART) drug treatment, HIV can be controlled, its progression can be significantly slowed, and gradually become a "chronic disease". In theory, before the emergence of curative drugs, AIDS patients need to take medication for life. Although there are relatively many existing antiviral therapies, they all have a clear disadvantage: long taking cycles and short intervals. Once the medication is stopped or missed, it will lead to the deterioration of AIDS; and long-term medication may also cause problems such as drug resistance and liver damage. Historically, vaccines have been the most effective means of preventing or even eradicating infectious diseases. They can safely and cost-effectively prevent disease, disability and death. HIV vaccine is a potential vaccine that can be both a preventive vaccine and a therapeutic vaccine, meaning that it can protect individuals from HIV infection and treat HIV-infected people. In theory, it can have a significant impact on transmission rates and help control epidemics.

The North American market for HIV Vaccine is projected to increase from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

The Asia-Pacific market for HIV Vaccine is projected to rise from US$ million in 2025 to US$ million by 2032, at a CAGR of % over 2026–2032.

Major global manufacturers of HIV Vaccine include Johnson and Johnson (Janssen), Sanofi-Pasteur, Uvax Bio, AELIX Therapeutics, IAVI, HKUMed, etc. In 2025, the world's top three vendors accounted for approximately % of revenue.

This report delivers a comprehensive overview of the global HIV Vaccine market, with both quantitative and qualitative analyses, to help readers develop growth strategies, assess the competitive landscape, evaluate their position in the current market, and make informed business decisions regarding HIV Vaccine. The HIV Vaccine market size, estimates, and forecasts are provided in terms of sales volume (Million Person) and revenue (US$ millions), with 2025 as the base year and historical and forecast data for 2021–2032.

The report segments the global HIV Vaccine market comprehensively. Regional market sizes by Type, by Application, , and by company are also provided. For deeper insight, the report profiles the competitive landscape, key competitors, and their respective market rankings, and discusses technological trends and new product developments.

This report will assist HIV Vaccine manufacturers, new entrants, and companies across the industry value chain with information on revenues, sales volume, and average prices for the overall market and its sub-segments, by company, by Type, by Application, and by region.

Market Segmentation

Scope of HIV Vaccine Market Report

Chapter Outline

1.1 Product Definition

1.2 HIV Vaccine by Type

1.2.1 Global HIV Vaccine Market Value by Type: 2025 vs 2032

1.2.2 Viral Vector Vaccines

1.2.3 Recombinant Protein Vaccines

1.2.4 Nucleic Acid Vaccines (including mRNA Vaccines)

1.2.5 Other Vaccines

1.3 HIV Vaccine by Application

1.3.1 Global HIV Vaccine Market Value by Application: 2025 vs 2032

1.3.2 Preventive Vaccine

1.3.3 Therapeutic Vaccine

1.4 Global HIV Vaccine Market Size Estimates and Forecasts

1.4.1 Global HIV Vaccine Revenue 2021–2032

1.4.2 Global HIV Vaccine Sales 2021–2032

1.4.3 Global HIV Vaccine Market Average Price (2021–2032)

1.5 Assumptions and Limitations

2.1 Global HIV Vaccine Sales Market Share by Manufacturers (2021–2026)

2.2 Global HIV Vaccine Revenue Market Share by Manufacturers (2021–2026)

2.3 Global HIV Vaccine Average Price by Manufacturers (2021–2026)

2.4 Global Key Players of HIV Vaccine, Industry Ranking, 2023 vs 2024 vs 2025

2.5 Global Key Manufacturers of HIV Vaccine, Manufacturing Sites and Headquarters

2.6 Global Key Manufacturers of HIV Vaccine, Product Types and Applications

2.7 Global Key Manufacturers of HIV Vaccine, Date of Entry into the Industry

2.8 Global HIV Vaccine Market Competitive Situation and Trends

2.8.1 Global HIV Vaccine Market Concentration Rate

2.8.2 The Top 5 and Top 10 Global HIV Vaccine Players Market Share by Revenue

2.8.3 Global HIV Vaccine Market Share by Company Tier (Tier 1, Tier 2, Tier 3)

2.9 Manufacturers Mergers & Acquisitions, Expansion Plans

3.1 Global HIV Vaccine Market Size by Region: 2021 vs 2025 vs 2032

3.2 Global HIV Vaccine Sales by Region: 2021–2032

3.2.1 Global HIV Vaccine Sales by Region: 2021–2026

3.2.2 Global HIV Vaccine Sales by Region: 2027–2032

3.3 Global HIV Vaccine Revenue by Region: 2021–2032

3.3.1 Global HIV Vaccine Revenue by Region: 2021–2026

3.3.2 Global HIV Vaccine Revenue by Region: 2027–2032

3.4 North America HIV Vaccine Market Facts & Figures by Country

3.4.1 North America HIV Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.4.2 North America HIV Vaccine Sales by Country (2021–2032)

3.4.3 North America HIV Vaccine Revenue by Country (2021–2032)

3.4.4 United States

3.4.5 Canada

3.5 Europe HIV Vaccine Market Facts & Figures by Country

3.5.1 Europe HIV Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.5.2 Europe HIV Vaccine Sales by Country (2021–2032)

3.5.3 Europe HIV Vaccine Revenue by Country (2021–2032)

3.5.4 Germany

3.5.5 France

3.5.6 U.K.

3.5.7 Italy

3.5.8 Russia

3.6 Asia Pacific HIV Vaccine Market Facts & Figures by Region

3.6.1 Asia Pacific HIV Vaccine Market Size by Region: 2021 vs 2025 vs 2032

3.6.2 Asia Pacific HIV Vaccine Sales by Region (2021–2032)

3.6.3 Asia Pacific HIV Vaccine Revenue by Region (2021–2032)

3.6.4 China

3.6.5 Japan

3.6.6 South Korea

3.6.7 India

3.6.8 Australia

3.6.9 China Taiwan

3.6.10 Southeast Asia

3.7 Latin America HIV Vaccine Market Facts & Figures by Country

3.7.1 Latin America HIV Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.7.2 Latin America HIV Vaccine Sales by Country (2021–2032)

3.7.3 Latin America HIV Vaccine Revenue by Country (2021–2032)

3.7.4 Mexico

3.7.5 Brazil

3.7.6 Argentina

3.8 Middle East and Africa HIV Vaccine Market Facts & Figures by Country

3.8.1 Middle East and Africa HIV Vaccine Market Size by Country: 2021 vs 2025 vs 2032

3.8.2 Middle East and Africa HIV Vaccine Sales by Country (2021–2032)

3.8.3 Middle East and Africa HIV Vaccine Revenue by Country (2021–2032)

3.8.4 Turkey

3.8.5 Saudi Arabia

3.8.6 UAE

4.1 Global HIV Vaccine Sales by Type (2021–2032)

4.1.1 Global HIV Vaccine Sales by Type (2021–2026)

4.1.2 Global HIV Vaccine Sales by Type (2027–2032)

4.1.3 Global HIV Vaccine Sales Market Share by Type (2021–2032)

4.2 Global HIV Vaccine Revenue by Type (2021–2032)

4.2.1 Global HIV Vaccine Revenue by Type (2021–2026)

4.2.2 Global HIV Vaccine Revenue by Type (2027–2032)

4.2.3 Global HIV Vaccine Revenue Market Share by Type (2021–2032)

4.3 Global HIV Vaccine Price by Type (2021–2032)

5.1 Global HIV Vaccine Sales by Application (2021–2032)

5.1.1 Global HIV Vaccine Sales by Application (2021–2026)

5.1.2 Global HIV Vaccine Sales by Application (2027–2032)

5.1.3 Global HIV Vaccine Sales Market Share by Application (2021–2032)

5.2 Global HIV Vaccine Revenue by Application (2021–2032)

5.2.1 Global HIV Vaccine Revenue by Application (2021–2026)

5.2.2 Global HIV Vaccine Revenue by Application (2027–2032)

5.2.3 Global HIV Vaccine Revenue Market Share by Application (2021–2032)

5.3 Global HIV Vaccine Price by Application (2021–2032)

6.1 Johnson and Johnson (Janssen)

6.1.1 Johnson and Johnson (Janssen) Company Information

6.1.2 Johnson and Johnson (Janssen) Description and Business Overview

6.1.3 Johnson and Johnson (Janssen) HIV Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.1.4 Johnson and Johnson (Janssen) HIV Vaccine Product Portfolio

6.1.5 Johnson and Johnson (Janssen) Recent Developments/Updates

6.2 Sanofi-Pasteur

6.2.1 Sanofi-Pasteur Company Information

6.2.2 Sanofi-Pasteur Description and Business Overview

6.2.3 Sanofi-Pasteur HIV Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.2.4 Sanofi-Pasteur HIV Vaccine Product Portfolio

6.2.5 Sanofi-Pasteur Recent Developments/Updates

6.3 Uvax Bio

6.3.1 Uvax Bio Company Information

6.3.2 Uvax Bio Description and Business Overview

6.3.3 Uvax Bio HIV Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.3.4 Uvax Bio HIV Vaccine Product Portfolio

6.3.5 Uvax Bio Recent Developments/Updates

6.4 AELIX Therapeutics

6.4.1 AELIX Therapeutics Company Information

6.4.2 AELIX Therapeutics Description and Business Overview

6.4.3 AELIX Therapeutics HIV Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.4.4 AELIX Therapeutics HIV Vaccine Product Portfolio

6.4.5 AELIX Therapeutics Recent Developments/Updates

6.5 IAVI

6.5.1 IAVI Company Information

6.5.2 IAVI Description and Business Overview

6.5.3 IAVI HIV Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.5.4 IAVI HIV Vaccine Product Portfolio

6.5.5 IAVI Recent Developments/Updates

6.6 HKUMed

6.6.1 HKUMed Company Information

6.6.2 HKUMed Description and Business Overview

6.6.3 HKUMed HIV Vaccine Sales, Revenue, and Gross Margin (2021–2026)

6.6.4 HKUMed HIV Vaccine Product Portfolio

6.6.5 HKUMed Recent Developments/Updates

7.1 HIV Vaccine Industry Chain Analysis

7.2 HIV Vaccine Raw Material Supply Analysis

7.2.1 Key Raw Materials

7.2.2 Raw Materials Key Suppliers

7.3 HIV Vaccine Production Mode & Process Analysis

7.4 HIV Vaccine Sales and Marketing

7.4.1 HIV Vaccine Sales Channels

7.4.2 HIV Vaccine Distributors

7.5 HIV Vaccine Customer Analysis

8.1 HIV Vaccine Industry Trends

8.2 HIV Vaccine Market Drivers

8.3 HIV Vaccine Market Challenges

8.4 HIV Vaccine Market Restraints

8.5 Impact of U.S. Tariffs

10.1 Methodology/Research Approach

10.1.1 Research Programs/Design

10.1.2 Market Size Estimation

10.1.3 Market Breakdown and Data Triangulation

10.2 Data Source

10.2.1 Secondary Sources

10.2.2 Primary Sources

10.3 Author List

10.4 Disclaimer

List of Tables

 Table 1. Global HIV Vaccine Market Value by Type (US$ Million), 2025 vs 2032

 Table 2. Global HIV Vaccine Market Value by Application (US$ Million), 2025 vs 2032

 Table 3. Global HIV Vaccine Market Competitive Situation by Manufacturers in 2025

 Table 4. Global HIV Vaccine Sales (Million Person) of Key Manufacturers (2021–2026)

 Table 5. Global HIV Vaccine Sales Market Share by Manufacturers (2021–2026)

 Table 6. Global HIV Vaccine Revenue (US$ Million) by Manufacturers (2021–2026)

 Table 7. Global HIV Vaccine Revenue Share by Manufacturers (2021–2026)

 Table 8. Global Market HIV Vaccine Average Price (US$/Person) of Key Manufacturers (2021–2026)

 Table 9. Global Key Players of HIV Vaccine, Industry Ranking, 2023 vs 2024 vs 2025

 Table 10. Global Key Manufacturers of HIV Vaccine, Manufacturing Sites and Headquarters

 Table 11. Global Key Manufacturers of HIV Vaccine, Product Types and Applications

 Table 12. Global Key Manufacturers of HIV Vaccine, Date of Entry into the Industry

 Table 13. Global Manufacturers Market Concentration Ratio (CR5 and HHI)

 Table 14. Global HIV Vaccine Companies by Tier (Tier 1, Tier 2, Tier 3), based on HIV Vaccine Revenue, 2025

 Table 15. Manufacturers Mergers & Acquisitions, Expansion Plans

 Table 16. Global HIV Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Table 17. Global HIV Vaccine Sales by Region (Million Person), 2021–2026

 Table 18. Global HIV Vaccine Sales Market Share by Region (2021–2026)

 Table 19. Global HIV Vaccine Sales by Region (Million Person), 2027–2032

 Table 20. Global HIV Vaccine Sales Market Share by Region (2027–2032)

 Table 21. Global HIV Vaccine Revenue by Region (US$ Million), 2021–2026

 Table 22. Global HIV Vaccine Revenue Market Share by Region (2021–2026)

 Table 23. Global HIV Vaccine Revenue by Region (US$ Million), 2027–2032

 Table 24. Global HIV Vaccine Revenue Market Share by Region (2027–2032)

 Table 25. North America HIV Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 26. North America HIV Vaccine Sales by Country (Million Person), 2021–2026

 Table 27. North America HIV Vaccine Sales by Country (Million Person), 2027–2032

 Table 28. North America HIV Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 29. North America HIV Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 30. Europe HIV Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 31. Europe HIV Vaccine Sales by Country (Million Person), 2021–2026

 Table 32. Europe HIV Vaccine Sales by Country (Million Person), 2027–2032

 Table 33. Europe HIV Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 34. Europe HIV Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 35. Asia Pacific HIV Vaccine Revenue by Region: 2021 vs 2025 vs 2032 (US$ Million)

 Table 36. Asia Pacific HIV Vaccine Sales by Region (Million Person), 2021–2026

 Table 37. Asia Pacific HIV Vaccine Sales by Region (Million Person), 2027–2032

 Table 38. Asia Pacific HIV Vaccine Revenue by Region (US$ Million), 2021–2026

 Table 39. Asia Pacific HIV Vaccine Revenue by Region (US$ Million), 2027–2032

 Table 40. Latin America HIV Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 41. Latin America HIV Vaccine Sales by Country (Million Person), 2021–2026

 Table 42. Latin America HIV Vaccine Sales by Country (Million Person), 2027–2032

 Table 43. Latin America HIV Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 44. Latin America HIV Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 45. Middle East and Africa HIV Vaccine Revenue by Country: 2021 vs 2025 vs 2032 (US$ Million)

 Table 46. Middle East and Africa HIV Vaccine Sales by Country (Million Person), 2021–2026

 Table 47. Middle East and Africa HIV Vaccine Sales by Country (Million Person), 2027–2032

 Table 48. Middle East and Africa HIV Vaccine Revenue by Country (US$ Million), 2021–2026

 Table 49. Middle East and Africa HIV Vaccine Revenue by Country (US$ Million), 2027–2032

 Table 50. Global HIV Vaccine Sales (Million Person) by Type (2021–2026)

 Table 51. Global HIV Vaccine Sales (Million Person) by Type (2027–2032)

 Table 52. Global HIV Vaccine Sales Market Share by Type (2021–2026)

 Table 53. Global HIV Vaccine Sales Market Share by Type (2027–2032)

 Table 54. Global HIV Vaccine Revenue (US$ Million) by Type (2021–2026)

 Table 55. Global HIV Vaccine Revenue (US$ Million) by Type (2027–2032)

 Table 56. Global HIV Vaccine Revenue Market Share by Type (2021–2026)

 Table 57. Global HIV Vaccine Revenue Market Share by Type (2027–2032)

 Table 58. Global HIV Vaccine Price (US$/Person) by Type (2021–2026)

 Table 59. Global HIV Vaccine Price (US$/Person) by Type (2027–2032)

 Table 60. Global HIV Vaccine Sales (Million Person) by Application (2021–2026)

 Table 61. Global HIV Vaccine Sales (Million Person) by Application (2027–2032)

 Table 62. Global HIV Vaccine Sales Market Share by Application (2021–2026)

 Table 63. Global HIV Vaccine Sales Market Share by Application (2027–2032)

 Table 64. Global HIV Vaccine Revenue (US$ Million) by Application (2021–2026)

 Table 65. Global HIV Vaccine Revenue (US$ Million) by Application (2027–2032)

 Table 66. Global HIV Vaccine Revenue Market Share by Application (2021–2026)

 Table 67. Global HIV Vaccine Revenue Market Share by Application (2027–2032)

 Table 68. Global HIV Vaccine Price (US$/Person) by Application (2021–2026)

 Table 69. Global HIV Vaccine Price (US$/Person) by Application (2027–2032)

 Table 70. Johnson and Johnson (Janssen) Company Information

 Table 71. Johnson and Johnson (Janssen) Description and Business Overview

 Table 72. Johnson and Johnson (Janssen) HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person), and Gross Margin (2021–2026)

 Table 73. Johnson and Johnson (Janssen) HIV Vaccine Product

 Table 74. Johnson and Johnson (Janssen) Recent Developments/Updates

 Table 75. Sanofi-Pasteur Company Information

 Table 76. Sanofi-Pasteur Description and Business Overview

 Table 77. Sanofi-Pasteur HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person), and Gross Margin (2021–2026)

 Table 78. Sanofi-Pasteur HIV Vaccine Product

 Table 79. Sanofi-Pasteur Recent Developments/Updates

 Table 80. Uvax Bio Company Information

 Table 81. Uvax Bio Description and Business Overview

 Table 82. Uvax Bio HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person), and Gross Margin (2021–2026)

 Table 83. Uvax Bio HIV Vaccine Product

 Table 84. Uvax Bio Recent Developments/Updates

 Table 85. AELIX Therapeutics Company Information

 Table 86. AELIX Therapeutics Description and Business Overview

 Table 87. AELIX Therapeutics HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person), and Gross Margin (2021–2026)

 Table 88. AELIX Therapeutics HIV Vaccine Product

 Table 89. AELIX Therapeutics Recent Developments/Updates

 Table 90. IAVI Company Information

 Table 91. IAVI Description and Business Overview

 Table 92. IAVI HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person), and Gross Margin (2021–2026)

 Table 93. IAVI HIV Vaccine Product

 Table 94. IAVI Recent Developments/Updates

 Table 95. HKUMed Company Information

 Table 96. HKUMed Description and Business Overview

 Table 97. HKUMed HIV Vaccine Sales (Million Person), Revenue (US$ Million), Price (US$/Person), and Gross Margin (2021–2026)

 Table 98. HKUMed HIV Vaccine Product

 Table 99. HKUMed Recent Developments/Updates

 Table 100. Key Raw Materials Lists

 Table 101. Raw Materials Key Suppliers Lists

 Table 102. HIV Vaccine Distributors List

 Table 103. HIV Vaccine Customers List

 Table 104. HIV Vaccine Market Trends

 Table 105. HIV Vaccine Market Drivers

 Table 106. HIV Vaccine Market Challenges

 Table 107. HIV Vaccine Market Restraints

 Table 108. Research Programs/Design for This Report

 Table 109. Key Data Information from Secondary Sources

 Table 110. Key Data Information from Primary Sources

 Table 111. Authors List of This Report

List of Figures

 Figure 1. Product Picture of HIV Vaccine

 Figure 2. Global HIV Vaccine Market Value by Type (US$ Million), 2021–2032

 Figure 3. Global HIV Vaccine Market Share by Type: 2025 & 2032

 Figure 4. Viral Vector Vaccines Product Picture

 Figure 5. Recombinant Protein Vaccines Product Picture

 Figure 6. Nucleic Acid Vaccines (including mRNA Vaccines) Product Picture

 Figure 7. Other Vaccines Product Picture

 Figure 8. Global HIV Vaccine Market Value by Application (US$ Million), 2021–2032

 Figure 9. Global HIV Vaccine Market Share by Application: 2025 & 2032

 Figure 10. Preventive Vaccine

 Figure 11. Therapeutic Vaccine

 Figure 12. Global HIV Vaccine Revenue, (US$ Million), 2021 vs 2025 vs 2032

 Figure 13. Global HIV Vaccine Market Size (US$ Million), 2021–2032

 Figure 14. Global HIV Vaccine Sales (Million Person), 2021–2032

 Figure 15. Global HIV Vaccine Average Price (US$/Person), 2021–2032

 Figure 16. HIV Vaccine Report Years Considered

 Figure 17. HIV Vaccine Sales Share by Manufacturers in 2025

 Figure 18. Global HIV Vaccine Revenue Share by Manufacturers in 2025

 Figure 19. Top 5 and Top 10 Global HIV Vaccine Players: Market Share by Revenue in HIV Vaccine in 2025

 Figure 20. HIV Vaccine Market Share by Company Type (Tier 1, Tier 2, and Tier 3): 2021 vs 2025

 Figure 21. Global HIV Vaccine Market Size by Region (US$ Million): 2021 vs 2025 vs 2032

 Figure 22. North America HIV Vaccine Sales Market Share by Country (2021–2032)

 Figure 23. North America HIV Vaccine Revenue Market Share by Country (2021–2032)

 Figure 24. United States HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 25. Canada HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 26. Europe HIV Vaccine Sales Market Share by Country (2021–2032)

 Figure 27. Europe HIV Vaccine Revenue Market Share by Country (2021–2032)

 Figure 28. Germany HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 29. France HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 30. U.K. HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 31. Italy HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 32. Russia HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 33. Asia Pacific HIV Vaccine Sales Market Share by Region (2021–2032)

 Figure 34. Asia Pacific HIV Vaccine Revenue Market Share by Region (2021–2032)

 Figure 35. China HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 36. Japan HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 37. South Korea HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 38. India HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 39. Australia HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 40. China Taiwan HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 41. Southeast Asia HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 42. Latin America HIV Vaccine Sales Market Share by Country (2021–2032)

 Figure 43. Latin America HIV Vaccine Revenue Market Share by Country (2021–2032)

 Figure 44. Mexico HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 45. Brazil HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 46. Argentina HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 47. Middle East and Africa HIV Vaccine Sales Market Share by Country (2021–2032)

 Figure 48. Middle East and Africa HIV Vaccine Revenue Market Share by Country (2021–2032)

 Figure 49. Turkey HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 50. Saudi Arabia HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 51. UAE HIV Vaccine Revenue Growth Rate (US$ Million), 2021–2032

 Figure 52. Global Sales Market Share of HIV Vaccine by Type (2021–2032)

 Figure 53. Global Revenue Market Share of HIV Vaccine by Type (2021–2032)

 Figure 54. Global HIV Vaccine Price (US$/Person) by Type (2021–2032)

 Figure 55. Global Sales Market Share of HIV Vaccine by Application (2021–2032)

 Figure 56. Global Revenue Market Share of HIV Vaccine by Application (2021–2032)

 Figure 57. Global HIV Vaccine Price (US$/Person) by Application (2021–2032)

 Figure 58. HIV Vaccine Value Chain

 Figure 59. Channels of Distribution (Direct Vs Distribution)

 Figure 60. Bottom-up and Top-down Approaches for This Report

 Figure 61. Data Triangulation

 Figure 62. Key Executives Interviewed